Biomea Fusion, Inc. Operating Cash Flow
Biomea Fusion, Inc. (BMEA) reported Operating Cash Flow of -$21.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.03M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$11.67M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$13.94M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$11.55M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$70.37M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$119.89M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$96.59M.
- Biomea Fusion, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$62.42M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$21.70M 10-Q · filed 2026-08-05 | -$35.64M derived: sum of 3 quarters · filed 2026-08-05 | -$47.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.67M 10-Q · filed 2026-05-11 | -$25.61M derived: sum of 2 quarters · filed 2026-05-11 | -$37.16M derived: sum of 3 quarters · filed 2026-05-11 | -$56.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$25.49M derived: sum of 2 quarters · filed 2026-03-24 | -$44.70M derived: sum of 3 quarters · filed 2026-08-05 | -$70.37M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$11.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$30.76M derived: sum of 2 quarters · filed 2026-08-05 | -$56.43M 10-Q · filed 2025-11-04 | -$86.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$19.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$44.88M 10-Q · filed 2026-08-05 | -$74.88M derived: sum of 3 quarters · filed 2026-08-05 | -$100.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$25.67M 10-Q · filed 2026-05-11 | -$55.67M derived: sum of 2 quarters · filed 2026-05-11 | -$80.89M derived: sum of 3 quarters · filed 2026-05-11 | -$113.53M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$55.22M derived: sum of 2 quarters · filed 2026-03-24 | -$87.86M derived: sum of 3 quarters · filed 2026-03-24 | -$119.89M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$25.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$57.86M derived: sum of 2 quarters · filed 2025-11-04 | -$89.89M 10-Q · filed 2025-11-04 | -$112.73M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | -$32.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$64.67M 10-Q · filed 2025-08-05 | -$87.51M derived: sum of 3 quarters · filed 2026-03-24 | -$111.41M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | -$32.03M 10-Q · filed 2025-05-05 | -$54.87M derived: sum of 2 quarters · filed 2026-03-24 | -$78.77M derived: sum of 3 quarters · filed 2026-03-24 | -$104.58M derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | -$22.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$46.74M derived: sum of 2 quarters · filed 2026-03-24 | -$72.55M derived: sum of 3 quarters · filed 2026-03-24 | -$96.59M 10-K · filed 2026-03-24 |
| 2023-09-30 | -$23.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$49.71M derived: sum of 2 quarters · filed 2024-10-29 | -$73.75M 10-Q · filed 2024-10-29 | -$93.96M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | -$25.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$49.86M 10-Q · filed 2024-07-31 | -$70.06M derived: sum of 3 quarters · filed 2025-03-31 | -$86.85M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$24.04M 10-Q · filed 2024-05-02 | -$44.24M derived: sum of 2 quarters · filed 2025-03-31 | -$61.04M derived: sum of 3 quarters · filed 2025-03-31 | -$76.47M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | -$20.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$37.00M derived: sum of 2 quarters · filed 2025-03-31 | -$52.42M derived: sum of 3 quarters · filed 2025-03-31 | -$62.42M 10-K · filed 2025-03-31 |
| 2022-09-30 | -$16.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | -$32.22M derived: sum of 2 quarters · filed 2023-10-30 | -$42.22M 10-Q · filed 2023-10-30 | -$58.12M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | -$15.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | -$25.42M 10-Q · filed 2023-07-31 | -$41.32M derived: sum of 3 quarters · filed 2024-03-28 | -$50.31M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | -$9.99M 10-Q · filed 2023-05-02 | -$25.89M derived: sum of 2 quarters · filed 2024-03-28 | -$34.88M derived: sum of 3 quarters · filed 2024-03-28 | -$41.36M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$15.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$24.89M derived: sum of 2 quarters · filed 2024-03-28 | -$31.36M derived: sum of 3 quarters · filed 2024-03-28 | -$35.44M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$15.46M derived: sum of 2 quarters · filed 2022-11-07 | -$19.54M 10-Q · filed 2022-11-07 | -$22.27M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | -$6.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$10.55M 10-Q · filed 2022-08-01 | -$13.29M derived: sum of 3 quarters · filed 2023-03-28 | -$14.39M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$4.08M 10-Q · filed 2022-05-16 | -$6.81M derived: sum of 2 quarters · filed 2023-03-28 | -$7.91M derived: sum of 3 quarters · filed 2023-03-28 | -$8.28M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$3.84M derived: sum of 2 quarters · filed 2023-03-28 | -$4.21M derived: sum of 3 quarters · filed 2023-03-28 | -$4.46M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$1.47M derived: sum of 2 quarters · filed 2021-11-03 | -$1.72M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$369.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$621.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$252.00K 10-Q · filed 2021-05-27 | |||
| 2019-12-31 | -$1.28M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |